AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

NeuroKaire Secures $10M to Transform Precision Medicine in Psychiatry and Neurology

Home
/
update
/
details

Singapore's NPM Programme Partners with PacBio to Advance HiFi Sequencing in Southeast Asia

NextEdge Admin

06 Aug 2024

2 min 28 sec

PacBio , a leader in high-quality sequencing solutions, has been selected by Precision Health Research, Singapore (PRECISE) for its Long-Read Sequencing Flagship Project. This initiative, part of Singapore’s National Precision Medicine (NPM) programme, aims to create the largest long-read sequencing dataset in Southeast Asia, advancing precision medicine in Singapore by providing new insights into the Asian genome.

The partnership utilizes PacBio’s Revio HiFi sequencing system, known for its comprehensive genomic coverage and ability to detect large structural variations and DNA methylation. This technology will enable detailed analysis of genetic diversity, disease mechanisms, and clinical diagnoses within Singapore’s multi-ethnic population. The multi-omics approach combines whole genome sequencing, RNA full-length sequencing, fiber sequencing, and methylation analysis.

Christian Henry, President and CEO of PacBio, expressed his enthusiasm for the collaboration, highlighting the system's capability to deliver complete and accurate genomes. The project will generate phased methylome and genomic data with specific HiFi depth for various applications, including reference genomes, multi-omics analysis, and research cases in cancer and rare diseases.

PacBio will establish advanced sequencing infrastructure in Singapore, featuring a centralised library preparation facility and sequencing laboratory. Macrogen Asia Pacific Pte Ltd, a CAP-accredited service provider, will handle the sequencing production. Data integration and secure access will be managed through AWS cloud storage.

This partnership represents a significant commitment from both PacBio and PRECISE to drive scientific breakthroughs and enhance clinical outcomes in precision medicine, leveraging cutting-edge technology and local expertise to shape the future of healthcare in Singapore and beyond.